Business Context and Reporting Period
Veracyte, Inc. filed this Form 8-K on January 3, 2019, reporting a material event that occurred on December 28, 2018. The filing details the entry into a Diagnostics Development Agreement with Johnson & Johnson Services, Inc. (JJSI).
Key Financial Metrics and Agreement Terms
This filing reports on a strategic partnership rather than periodic financial performance. Key financial terms of the agreement include:
- Upfront Payment: JJSI will pay Veracyte an initial $5 million for RNA sequencing data on existing Percepta v.2 cohorts.
- Milestone Payments: JJSI may pay up to an additional $15 million contingent on achieving specific development and reimbursement milestones for Percepta v.2 and NasaRISK.
- Revenue Sharing: Veracyte will pay JJSI royalties for ten years following the first commercial sale of the products. Rates are 1% of net cash collections for Percepta v.2 and low-single digits for NasaRISK, dependent on sample volume and timing.
The filing text does not provide clear values for Veracyte's current revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Strategic Developments
The primary material change is the execution of the collaboration agreement to develop two new lung cancer diagnostics:
- Percepta v.2: A next-generation bronchial genomic classifier.
- NasaRISK: A nasal genomic classifier.
Under the agreement, JJSI grants Veracyte a non-exclusive license to use JJSI clinical data and samples for these diagnostics. Conversely, Veracyte grants JJSI a non-exclusive license to use data from the AEGIS and Percepta Registry studies for therapeutic purposes and companion diagnostic development.
Outlook, Risks, and Intellectual Property
Intellectual Property Ownership: Veracyte will solely own diagnostic technology and IP generated under the agreement. JJSI will solely own therapeutic technology and IP. Other generated technology will be jointly owned.
Commitments: Veracyte is obligated to use commercially reasonable efforts to seek regulatory approval and commercialize the products in the U.S. and other agreed-upon countries.
Termination: For the first two years, the agreement can only be terminated for uncured material breach or insolvency.
The filing does not provide specific management commentary on future financial guidance or detailed risk factors beyond the standard contractual terms.
Investor Verification Checklist
- Verify the specific milestones required to trigger the up to $15 million in additional payments.
- Confirm the exact "low-single digit" royalty percentage for NasaRISK based on sample volume tiers.
- Review the full text of the Diagnostics Development Agreement filed as an exhibit to the 2018 Form 10-K for complete legal terms.
- Assess the impact of the $5 million upfront payment on Veracyte's immediate cash position and revenue recognition policies.